542 related articles for article (PubMed ID: 23530502)
21. Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors.
Qian XJ; Li YT; Yu Y; Yang F; Deng R; Ji J; Jiao L; Li X; Wu RY; Chen WD; Feng GK; Zhu XF
Oncotarget; 2015 Mar; 6(7):5134-46. PubMed ID: 25762617
[TBL] [Abstract][Full Text] [Related]
22. Dual mTOR/PI3K inhibitor NVP‑BEZ235 arrests colorectal cancer cell growth and displays differential inhibition of 4E‑BP1.
Alqurashi N; Hashimi SM; Alowaidi F; Ivanovski S; Wei MQ
Oncol Rep; 2018 Aug; 40(2):1083-1092. PubMed ID: 29845289
[TBL] [Abstract][Full Text] [Related]
23. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells.
Treeck O; Wackwitz B; Haus U; Ortmann O
Gynecol Oncol; 2006 Aug; 102(2):292-9. PubMed ID: 16443261
[TBL] [Abstract][Full Text] [Related]
24. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
[TBL] [Abstract][Full Text] [Related]
25. The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
Grozinsky-Glasberg S; Rubinfeld H; Nordenberg Y; Gorshtein A; Praiss M; Kendler E; Feinmesser R; Grossman AB; Shimon I
Mol Cell Endocrinol; 2010 Feb; 315(1-2):87-94. PubMed ID: 19815051
[TBL] [Abstract][Full Text] [Related]
26. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
27. Targeting the AIB1 oncogene through mammalian target of rapamycin inhibition in the mammary gland.
Torres-Arzayus MI; Yuan J; DellaGatta JL; Lane H; Kung AL; Brown M
Cancer Res; 2006 Dec; 66(23):11381-8. PubMed ID: 17145884
[TBL] [Abstract][Full Text] [Related]
28. Tailored therapeutic strategies for synovial sarcoma: receptor tyrosine kinase pathway analyses predict sensitivity to the mTOR inhibitor RAD001.
Yasui H; Naka N; Imura Y; Outani H; Kaneko K; Hamada K; Sasagawa S; Araki N; Ueda T; Itoh K; Myoui A; Yoshikawa H
Cancer Lett; 2014 May; 347(1):114-22. PubMed ID: 24491407
[TBL] [Abstract][Full Text] [Related]
29. Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis.
Farhan MA; Carmine-Simmen K; Lewis JD; Moore RB; Murray AG
PLoS One; 2015; 10(8):e0135245. PubMed ID: 26295809
[TBL] [Abstract][Full Text] [Related]
30. Synergistic anti-tumor effects of RAD001 with MEK inhibitors in neuroendocrine tumors: a potential mechanism of therapeutic limitation of mTOR inhibitor.
Iida S; Miki Y; Ono K; Akahira J; Nakamura Y; Suzuki T; Sasano H
Mol Cell Endocrinol; 2012 Mar; 350(1):99-106. PubMed ID: 22178087
[TBL] [Abstract][Full Text] [Related]
31. PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth.
Sharma N; Nanta R; Sharma J; Gunewardena S; Singh KP; Shankar S; Srivastava RK
Oncotarget; 2015 Oct; 6(31):32039-60. PubMed ID: 26451606
[TBL] [Abstract][Full Text] [Related]
32. Alterations of hypoxia-induced factor signaling pathway due to mammalian target of rapamycin (mTOR) suppression in ovarian clear cell adenocarcinoma: in vivo and in vitro explorations for clinical trial.
Hirasawa T; Miyazawa M; Yasuda M; Shida M; Ikeda M; Kajiwara H; Matsui N; Fujita M; Muramatsu T; Mikami M
Int J Gynecol Cancer; 2013 Sep; 23(7):1210-8. PubMed ID: 23899586
[TBL] [Abstract][Full Text] [Related]
33. The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study.
Macaskill EJ; Bartlett JM; Sabine VS; Faratian D; Renshaw L; White S; Campbell FM; Young O; Williams L; Thomas JS; Barber MD; Dixon JM
Breast Cancer Res Treat; 2011 Aug; 128(3):725-34. PubMed ID: 20941539
[TBL] [Abstract][Full Text] [Related]
34. mTOR inhibitor for the treatment of hepatocellular carcinoma.
Kudo M
Dig Dis; 2011; 29(3):310-5. PubMed ID: 21829022
[TBL] [Abstract][Full Text] [Related]
35. RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer.
Wang ZG; Fukazawa T; Nishikawa T; Watanabe N; Sakurama K; Motoki T; Hatakeyama S; Omori O; Ohara T; Tanabe S; Fujiwara Y; Takaoka M; Shirakawa Y; Yamatsuji T; Tanaka N; Naomoto Y
Oncol Rep; 2010 Apr; 23(4):1167-72. PubMed ID: 20204306
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological targeting of mammalian target of rapamycin inhibits ovarian granulosa cell tumor growth.
Rico C; Laguë MN; Lefèvre P; Tsoi M; Dodelet-Devillers A; Kumar V; Lapointe E; Paquet M; Nadeau MÈ; Boerboom D
Carcinogenesis; 2012 Nov; 33(11):2283-92. PubMed ID: 22871496
[TBL] [Abstract][Full Text] [Related]
37. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
Huang Y; Chen Y; Mei Q; Chen Y; Yu S; Xia S
Oncol Rep; 2013 Jun; 29(6):2486-92. PubMed ID: 23525575
[TBL] [Abstract][Full Text] [Related]
38. Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001.
Kuo SH; Hsu CH; Chen LT; Lu YS; Lin CH; Yeh PY; Jeng HJ; Gao M; Yeh KH; Cheng AL
Eur J Cancer; 2011 May; 47(8):1244-57. PubMed ID: 21334199
[TBL] [Abstract][Full Text] [Related]
39. 15(S)-hydroxyeicosatetraenoic acid induces angiogenesis via activation of PI3K-Akt-mTOR-S6K1 signaling.
Zhang B; Cao H; Rao GN
Cancer Res; 2005 Aug; 65(16):7283-91. PubMed ID: 16103079
[TBL] [Abstract][Full Text] [Related]
40. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]